HomeCompareMKKGY vs MAIN

MKKGY vs MAIN: Dividend Comparison 2026

MKKGY yields 2.01% · MAIN yields 7.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MAIN wins by $47.86M in total portfolio value
10 years
MKKGY
MKKGY
● Live price
2.01%
Share price
$24.90
Annual div
$0.50
5Y div CAGR
46.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$86.6K
Annual income
$27,878.31
Full MKKGY calculator →
MAIN
Main Street Capital Corporation
● Live price
7.09%
Share price
$51.65
Annual div
$3.66
5Y div CAGR
72.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.95M
Annual income
$40,208,699.11
Full MAIN calculator →

Portfolio growth — MKKGY vs MAIN

📍 MAIN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMKKGYMAIN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MKKGY + MAIN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MKKGY pays
MAIN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MKKGY
Annual income on $10K today (after 15% tax)
$170.81/yr
After 10yr DRIP, annual income (after tax)
$23,696.56/yr
MAIN
Annual income on $10K today (after 15% tax)
$602.32/yr
After 10yr DRIP, annual income (after tax)
$34,177,394.24/yr
At 15% tax rate, MAIN beats the other by $34,153,697.68/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MKKGY + MAIN for your $10,000?

MKKGY: 50%MAIN: 50%
100% MAIN50/50100% MKKGY
Portfolio after 10yr
$24.02M
Annual income
$20,118,288.71/yr
Blended yield
83.77%
📊

Analyst Conviction Gap

Where Wall Street is split right now

MKKGY
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
2.6
Piotroski
7/9
MAIN
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$65.25
+26.3% upside vs current
Range: $60.00 — $70.00
Altman Z
1.7
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MKKGY buys
0
MAIN buys
0
PoliticianChamberTickerTypeAmountDate
Daniel Goldman🏢 House$MKKGY▼ Sell$1,001 - $15,0002023-07-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMKKGYMAIN
Forward yield2.01%7.09%
Annual dividend / share$0.50$3.66
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR46.8%72.7%
Portfolio after 10y$86.6K$47.95M
Annual income after 10y$27,878.31$40,208,699.11
Total dividends collected$60.8K$46.82M
Payment frequencyquarterlymonthly
SectorStockBDC
Analyst consensusBuyHold

Year-by-year: MKKGY vs MAIN ($10,000, DRIP)

YearMKKGY PortfolioMKKGY Income/yrMAIN PortfolioMAIN Income/yrGap
1← crossover$10,995$294.99$12,464$1,223.78$1.5KMAIN
2$12,210$444.99$16,353$2,343.58$4.1KMAIN
3$13,742$677.95$23,105$4,724.42$9.4KMAIN
4$15,751$1,046.87$36,226$10,256.23$20.5KMAIN
5$18,500$1,646.22$65,426$24,707.64$46.9KMAIN
6$22,448$2,652.71$142,101$68,562.02$119.7KMAIN
7$28,435$4,416.03$388,521$228,799.95$360.1KMAIN
8$38,100$7,674.63$1,397,868$961,169.80$1.36MMAIN
9$54,875$14,108.24$6,884,663$5,313,459.69$6.83MMAIN
10$86,595$27,878.31$47,947,060$40,208,699.11$47.86MMAIN

MKKGY vs MAIN: Complete Analysis 2026

MKKGYStock

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment also provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. The Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

Full MKKGY Calculator →

MAINBDC

Main Street Capital Corporation is a business development company specializes in equity capital to lower middle market companies. The firm specializing in recapitalizations, management buyouts, refinancing, family estate planning, management buyouts, refinancing, industry consolidation, mature, later stage emerging growth. The firm also provides debt capital to middle market companies for acquisitions, management buyouts, growth financings, recapitalizations and refinancing. The firm seeks to partner with entrepreneurs, business owners and management teams and generally provides one stop financing alternatives within its lower middle market portfolio. It prefers to invest in air freight and logistics, auto components, building products, chemicals, commercial services, computers, construction and engineering, consumer finance, consumer services, electronic equipment, energy equipment and services, financial services, health care equipment, health care providers, hotels, restaurants, and leisure, internet software and services, IT Services, machinery, oil, gas and consumable fuels, paper and forest products, professional and industrial services, road and rail, software, specialty retail, telecommunication, consumer discretionary, energy, materials, technology, and transportation. The firm typically invests in lower middle market companies generally with annual revenues between $5 million and $300 million. It prefers to invest in ranging between $2 million and $75 million in equity investment and enterprise value in ranging between $3 million and $20 million. The firm typically prefers to invest in the range of $5 million and $50 million per transaction in debt investment value and in the range of $1 million and $20 million in annual EBITDA. The firm's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies. It takes 5 percent minority and up to 50 percent majority equity investments. Main Street Capital Corporation was founded in 2007 and is based in Houston, Texas with an additional office in Chojnów, Poland.

Full MAIN Calculator →
📬

Get this MKKGY vs MAIN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MKKGY vs SCHDMKKGY vs JEPIMKKGY vs OMKKGY vs KOMKKGY vs ARCCMKKGY vs HTGCMKKGY vs GBDCMKKGY vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.